(Q38528624)

3 September 2017

1 reference

title

From bench to bedside and back again: translational research in autoinflammation (English)

1 reference

3 September 2017

3

1 reference

3 September 2017

Dirk Holzinger

1

1 reference

3 September 2017

Christoph Kessel

series ordinal

2

1 reference

3 September 2017

Marco Gattorno

series ordinal

4

1 reference

3 September 2017

language of work or name

English

0 references

publication date

16 June 2015

1 reference

Nature Reviews Rheumatology

3 September 2017

1 reference

3 September 2017

11

1 reference

3 September 2017

10

1 reference

3 September 2017

573-585

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2015.79

3 September 2017

0 references

cites work

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Natural history and outcome in systemic AA amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Human NLRP3 inflammasome senses multiple types of bacterial RNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Functions of NOD-Like Receptors in Human Diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Use of canakinumab in the cryopyrin-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL-1β production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Type I interferonopathies: mendelian type I interferon up-regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Activated STING in a vascular and pulmonary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The German etanercept registry for treatment of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Diagnostic potential of hepcidin testing in pediatrics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Beneficial response to interleukin 1 receptor antagonist in traps

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Successful Treatment of Tumor Necrosis Factor Receptor–Associated Periodic Syndrome With Canakinumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interplay between redox status and inflammasome activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The meaning of clinical remission in polyarticular juvenile idiopathic arthritis: gene expression profiling in peripheral blood mononuclear cells identifies distinct disease states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Proinflammatory S100A12 can activate human monocytes via Toll-like receptor 4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-18 and the pathogenesis of inflammatory diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A Role for IL-18 in Neutrophil Activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Overview of interleukin-18: more than an interferon-gamma inducing factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Molecular mechanisms of amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

AA amyloidosis complicating the hereditary periodic fever syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Systems approaches to human autoimmune diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Redox control of NLRP3 inflammasome activation in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

An inherited mutation in NLRC4 causes autoinflammation in human and mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-γ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Enhanced TLR-MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Impaired podosome formation and invasive migration of macrophages from patients with a PSTPIP1 mutation and PAPA syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Mutations in NALP12 cause hereditary periodic fever syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Inflammatory bowel disease and mutations affecting the interleukin-10 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

PSORS2 is due to mutations in CARD14.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Early-onset stroke and vasculopathy associated with mutations in ADA2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2015.79

Interleukin-18, a proinflammatory cytokine.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26077920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prevalence of subclinical amyloidosis in ankylosing spondylitis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26077920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26077920

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRRHEUM.2015.79

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference